Health claim
“Immunotherapy with pembrolizumab is approved for prostate cancer that is MSI‑high or has high tumor mutational burden.”
Claim extracted — not yet reviewedHigh riskmedications
This claim has been extracted from the video but has not yet been fully reviewed against published evidence. Treat with appropriate caution.
Evidence Summary
This claim has not yet been reviewed against the literature.
Extracted from
Advances in Prostate Cancer Treatment: Here's What Men Need to KnowMedStar Washington Hospital Center
The video provides an overview of recent advancements in prostate cancer treatment, emphasizing early detection and discussing new therapeutic options.
Watch breakdown →